Wall Street brokerages expect MEDNAX Inc (NYSE:MD) to report $0.83 earnings per share (EPS) for the current quarter, according to Zacks. Eight analysts have issued estimates for MEDNAX’s earnings, with the lowest EPS estimate coming in at $0.78 and the highest estimate coming in at $0.85. MEDNAX reported earnings of $1.00 per share during the same quarter last year, which indicates a negative year over year growth rate of 17%. The firm is expected to report its next earnings results on Tuesday, February 6th.

On average, analysts expect that MEDNAX will report full year earnings of $3.28 per share for the current fiscal year, with EPS estimates ranging from $3.10 to $3.32. For the next year, analysts expect that the firm will post earnings of $3.52 per share, with EPS estimates ranging from $3.32 to $3.65. Zacks’ EPS calculations are an average based on a survey of research analysts that that provide coverage for MEDNAX.

MEDNAX (NYSE:MD) last issued its quarterly earnings data on Wednesday, November 1st. The company reported $0.87 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.87. The business had revenue of $868.95 million for the quarter, compared to the consensus estimate of $864.78 million. MEDNAX had a net margin of 7.76% and a return on equity of 10.80%. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.09 EPS.

A number of analysts have recently weighed in on the stock. Piper Jaffray Companies assumed coverage on shares of MEDNAX in a research report on Wednesday, December 13th. They issued an “overweight” rating and a $58.00 target price on the stock. Jefferies Group reaffirmed a “hold” rating and issued a $46.00 target price on shares of MEDNAX in a research report on Tuesday, October 3rd. Citigroup reduced their target price on shares of MEDNAX from $52.00 to $47.00 and set a “neutral” rating on the stock in a research report on Friday, November 3rd. Zacks Investment Research raised shares of MEDNAX from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, Robert W. Baird upped their target price on shares of MEDNAX from $47.00 to $48.00 and gave the stock a “neutral” rating in a research report on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $53.70.

In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total transaction of $154,740.00. Following the transaction, the insider now owns 35,569 shares in the company, valued at approximately $1,834,649.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Cesar L. Alvarez sold 10,668 shares of the company’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $42.59, for a total transaction of $454,350.12. Following the transaction, the director now owns 44,215 shares in the company, valued at approximately $1,883,116.85. The disclosure for this sale can be found here. Insiders own 2.40% of the company’s stock.

Several large investors have recently modified their holdings of the company. Public Employees Retirement System of Ohio lifted its stake in shares of MEDNAX by 11.2% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 182,688 shares of the company’s stock worth $7,878,000 after purchasing an additional 18,459 shares during the period. GSA Capital Partners LLP bought a new position in shares of MEDNAX in the 3rd quarter worth approximately $554,000. CS Mckee LP lifted its stake in shares of MEDNAX by 22.8% in the 3rd quarter. CS Mckee LP now owns 337,000 shares of the company’s stock worth $14,531,000 after purchasing an additional 62,610 shares during the period. California Public Employees Retirement System lifted its stake in shares of MEDNAX by 5.0% in the 3rd quarter. California Public Employees Retirement System now owns 383,061 shares of the company’s stock worth $16,518,000 after purchasing an additional 18,261 shares during the period. Finally, Cubist Systematic Strategies LLC lifted its stake in shares of MEDNAX by 1,206.7% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 11,891 shares of the company’s stock worth $513,000 after purchasing an additional 10,981 shares during the period. Hedge funds and other institutional investors own 98.43% of the company’s stock.

MEDNAX (MD) traded up $0.61 during trading hours on Friday, hitting $52.02. 1,028,100 shares of the stock were exchanged, compared to its average volume of 1,099,048. The stock has a market cap of $4,814.82, a P/E ratio of 15.72, a PEG ratio of 1.66 and a beta of 0.40. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 0.62. MEDNAX has a 12-month low of $40.56 and a 12-month high of $72.13.

ILLEGAL ACTIVITY NOTICE: “Brokerages Anticipate MEDNAX Inc (MD) Will Post Earnings of $0.83 Per Share” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/12/20/brokerages-anticipate-mednax-inc-md-will-post-earnings-of-0-83-per-share.html.

MEDNAX Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Get a free copy of the Zacks research report on MEDNAX (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.